Month: December 2020

Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer CAMBRIDGE, UK, BOSTON

Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48, which is equal

Data were presented at the American Society of Hematology (ASH) Annual Meeting In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a